ASCO GI 2023 | Profiling of BRCA mutations in colorectal cancer

Heather Hampel, MS, City of Hope, Duarte, CA, comments on targeting and testing for BRCA1 and BRCA2 mutations in colorectal cancer. Whilst immune checkpoint inhibitors have been effective in microsatellite instability (MSI) high colorectal cancer, PARP inhibitors have been less efficacious in BRCA-mutated colorectal cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ